Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 1 of 2 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Initial Solvent Screening of Carbamazepine, Cimetidine, and Phenylbutazone: Part 1 of 2
The authors describe the importance of a rapid and an abbreviated screening strategy by initial solvent screening in 20-mL scintillation vials.


Pharmaceutical Technology
Volume 33, Issue 5, pp. 62-72


Figure 3a: Polymorphic flow chart showing the preparation methods for the four anhydrous polymorphs of carbamazepine, the thermal transition of Forms II–IV to Form I, and relationships (in blue) between carbamazepine Form I and Dihydrate I, and Form III and Dihydrate III.
Initial solvent screening. Under the initial solvent screening, the 19 solvents for scale-up previously listed were chosen (28–30, 70). About 5 mg of the API powders were weighed in a 20-mL scintillation vial the first time. Drops of a given solvent were titrated carefully by a micropipette into the vial with 1–2-min intermittent shaking until all the API powders were just dissolved at 25 C, maintained by a water bath. The solubility of the API powders in that particular solvent was approximated as the weight of the API powders in the vial divided by the total volume of the solvent added to the vial (i.e., the gravimetric method). A good solvent was defined as a solvent that gave a solubility of ≥ 5 mg/mL at 25 C and was designated by a yellow color. A bad solvent was designated by a red color later in the form space. The solubility of the API in the good solvent at 15, 40, and 60 C (or 50 C if the boiling point of a solvent is close to 60 C) was measured by the gravimetric method assuming the volumes of solvents were the volumes of solution and the volumes of solvents did not change significantly with temperature. Although the gravimetric method appeared to be imprecise, its advantages were its robustness, simplicity, the low amount of API required, the lack of necessity for calibration, and the absence of solvate and hydrate formation.


Figure 3b: Polymorphic flow chart showing the preparation methods for the four anhydrous polymorphs of cimetidine; the mechanical, thermal, and solution transition among Forms A–D; the preparation methods of the three monohydrates; and thermal transition (in blue) of cimetidine Monohydrate I to Forms A–C.
Solvent-miscibility studies. Of the 19 solvents, about 1-mL portions of each solvent in a pair were intermittently shaken together for about 1–2 min in a 20-mL scintillation vial (28–30). The solvent pair was considered to be miscible if no interfacial meniscus was observed after the contents of the vial were allowed to settle. Otherwise, the pair was regarded as immiscible and designated by a gray color later in the form space.


Figure 3c: Polymorphic flow chart showing preparation methods for the six anhydrous polymorphs of phenylbutazone; the thermal transition and the solution transformation among Forms α, β, δ, ε, and ζ; the methods of preparation of six solvates; and thermal transition (in blue) to Form δ.
Solids generation. Based on the predetermined solubility curves, solids generation of the API in each good solvent was achieved separately in a 20-mL scintillation vial by cooling the saturated API solution at 60 C and by moving the vial from a 60 C water bath to a 25 C water bath with intermittent shaking (28–30). The crystal habits of all solids were characterized by optical microscopy (OM) inside the vial under a slurry state. All solids were filtered, oven-dried under mild conditions at 40 C overnight, and characterized for their purity, polymorphism, solvates, and crystallinity by DSC, thermal gravimetric analysis (TGA), and transmission FTIR.

OM. An optical microscope (SZII, Olympus, Tokyo) equipped with a charged-coupled device (CCD) camera (SSC-DC50A, Sony, Tokyo) was used to take images of crystal habit.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here